US FDA Grants Approval for Incyte's Eczema Cream for Children
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 18 2025
0mins
Source: Reuters
FDA Approval: The U.S. FDA has approved Incyte's eczema cream, Opzelura, for children aged 2 to 11, marking it as the first topical JAK inhibitor approved for pediatric patients.
Market Impact: Incyte anticipates significant growth for Opzelura, projecting sales to double in the next five years, driven by its recent approvals for treating eczema in both children and adults.
Analyst Views on OGN
Wall Street analysts forecast OGN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for OGN is 8.50 USD with a low forecast of 5.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
0 Buy
1 Hold
4 Sell
Strong Sell
Current: 9.740
Low
5.00
Averages
8.50
High
12.00
Current: 9.740
Low
5.00
Averages
8.50
High
12.00
About OGN
Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
